Takeda
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.91 | 13 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.98 | 7 |
| phase 2 | ×0.94 | 5 |
| preclinical | ×0.80 | 3 |
Strategy profile
Based on 15 disclosed transactions, Takeda concentrates its licensing activity in Oncology, Hematology, and Other. Takeda pays a 0.90x discount to market median, with the strongest premiums in Oncology (0.91x). Their most common deal structure is License, with an average disclosed value of $1.9B. Most recent activity: 2026.
Premium by therapeutic area
How Takeda pays relative to peer medians in each TA
Pipeline coverage & gaps
Takeda has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 9 | $329M | $1.9B |
| Collaboration | 3 | — | $1.2B |
| Option | 2 | $100M | $700M |
| Acquisition | 1 | $4.0B | $6.0B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | AI-designed oncology candidate | Insilico Medicine | cancer | preclinical | — | $600M |
| 2026 | olverembatinib | Ascentage | cancer | unknown | — | $100M |
| 2026 | Gamma delta T-cell platform | GammaDelta Therapeutics | cancer and autoinflammatory diseases | preclinical | — | $100M |
| 2026 | Rusfertide | Protagonist | — | unknown | — | $475M |
| 2026 | olverembatinib | Ascentage Pharma | cancer | unknown | $100M | $100M |
| 2026 | AI-enabled molecular design including NeuralPLexer | Iambic Therapeutics | — | discovery | — | $1.7B |
| 2025 | IBI363, IBI343, IBI3001 (option) | Innovent Biologics | pancreatic cancer | phase_3 | $1.2B | $11.4B |
| 2025 | psoriasis | Nimbus Therapeutics | psoriasis | phase_3 | $4.0B | $6.0B |
| 2024 | anemia | Keros Therapeutics | anemia | phase_2 | $200M | $200M |
| 2024 | elritercept (KER-050) | Keros Therapeutics | lower-risk MDS and myelofibrosis-associated anemia | phase_3 | $200M | $1.3B |
| 2024 | elritercept | Keros Therapeutics | myelofibrosis | phase_2 | $200M | $1.3B |
| 2024 | elritercept | Keros Therapeutics | myelodysplastic syndromes | phase_2 | $200M | $1.3B |
| 2024 | elritercept | Keros Therapeutics | anemia due to very low, low, or intermediate risk myelodysplastic syndromes (MDS); myelofibrosis | phase_2 | $200M | $1.3B |
| 2024 | olverembatinib | Ascentage Pharma | chronic myeloid leukaemia and other haematological cancers | phase_2 | $100M | $1.3B |
| 2024 | CD38 | Hengrui Medicine | CLL | preclinical | — | $1.4B |
How this is computed
For each Takeda deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 19 disclosed deal premiums vs. peer medians. Raw premium 0.895, clamped to [0.7, 1.5].